Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. - Wikidata - wikimedia - TriplyDB

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

http://www.wikidata.org/entity/Q34323096

about

Twenty Years of PSA: From Prostate Antigen to Tumor Marker A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer Advancements in MR imaging of the prostate: from diagnosis to interventions Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial Prostate cancers in men with low PSA levels--must we find them?Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets Limitations and Prospects for Diffusion-Weighted MRI of the Prostate Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review Prostate MRI based on PI-RADS version 2: how we review and report The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements Current status of active surveillance in prostate cancer Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer PSA and beyond: alternative prostate cancer biomarkers Prostate Cancer for the Internist Diagnosis of prostate cancer via nanotechnological approach Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis Electrochemistry of nonconjugated proteins and glycoproteins. Toward sensors for biomedicine and glycomics Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer Emerging PSA-based tests to improve screening Population screening for prostate cancer: an overview of available studies and meta-analysis Landmarks in prostate cancer diagnosis: the biomarkers Kallikreins as biomarkers for prostate cancer Management of low (favourable)-risk prostate cancer Temporal trends and racial disparities in global prostate cancer prevalence A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential Prostate cancer: ESMO Consensus Conference Guidelines 2012 Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer Quantitative and Qualitative Analysis of Circulating Cell-Free DNA Can Be Used as an Adjuvant Tool for Prostate Cancer Screening: A Meta-Analysis Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?Serum methionine metabolites are risk factors for metastatic prostate cancer progression Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics SANIST: a rapid mass spectrometric SACI/ESI data acquisition and elaboration platform for verifying potential candidate biomarkers Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies Population-based screening for cancer: hope and hype.Discovery and validation of urinary biomarkers for prostate cancer Sonochemically fabricated microelectrode arrays for use as sensing platforms Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine Assessment of reproducibility in depletion and enrichment workflows for plasma proteomics using label-free quantitative data-independent LC-MS.Brain images, babies, and bathwater: critiquing critiques of functional neuroimaging.

P2860

Q24564782-367CD2EC-68EB-4D1C-8496-C7930EA93780 Q24569630-93156BAA-2FBC-4283-936B-A2BBAB8A7C37 Q24594047-EDC0DFCC-CB53-4625-A5C7-972F7F382257 Q24627834-66414DEB-1C9D-4ED3-AF5B-3156D0DAF3AE Q24628188-CD42DAD3-1D3B-4075-89ED-D7BD0DD123EB Q24629083-0C3D067F-DA99-484C-8C92-1F38449D02E7 Q26744802-21356190-D83A-4A3D-BE46-08849220A3C6 Q26748872-ED220543-0CBB-4ED9-881D-6E5FAD4DD42D Q26749289-DB5C82A5-F36E-4BCB-AB46-6CACA4682EFD Q26750672-275E0E43-E265-4A74-AF9E-B162609E967A Q26766307-8A203E07-49A6-4A19-B299-19D49BCC3E2D Q26767044-4056F8CA-94E7-461E-B13C-BC5D3A03B12C Q26770646-ACC09F53-B78B-48F0-B0DF-9DEE93AADF73 Q26771721-88BA8085-0E9F-4DCA-BF10-DF61C7ED2BF6 Q26777322-6D74EB66-C345-401C-9291-BED04821C55F Q26781093-6EC572E5-5093-4F3E-AD03-CDF215D29010 Q26822552-B007B972-9FF6-4743-ADE4-5AA918395037 Q26824913-8D0C7E97-E138-4DB2-AB02-4640C740BFD8 Q26828563-4A68525B-2A81-49DA-9D4E-CFE9B3D6F59F Q26829319-EE5B8DCB-D1EC-49F4-A0AD-D61C4DC70C69 Q26852523-A39CB78C-A416-42DB-83D2-D48CEDDA6150 Q26862434-912E23C5-5C64-4713-8FDA-1E2282E5B3EA Q26996501-E415FDAD-5670-4171-9521-1A1A4508E97E Q27006994-FF6A294E-A63B-4C0E-9952-BBB62801489D Q27022638-4B4617CB-5927-407B-9A68-C8C8CCF6AF86 Q27022847-11584D35-42CA-45C1-9471-0CC0D7A7E3F6 Q27304922-8D80F885-368A-487D-BE0A-2D2343DA205A Q28072148-AD2082C9-5957-42CF-B864-7347F1D14F45 Q28085419-92A9AA10-AEDD-4D33-B5CB-FDF5FBC03860 Q28391921-E74A86E3-96F6-4584-B104-5F4C91FE20F9 Q28476490-B498C87D-44A2-488D-BAFC-1E37C1C552A5 Q28482384-81A2958C-1562-480E-B634-AC5239FCEFC7 Q28822547-BBB28B79-F9C8-4885-A619-63A2E6FCCF32 Q28943405-A0192BFD-BCF8-4752-89D7-BAFB7BDE7E6E Q30251601-F483301B-1236-476D-AD21-2CCBE5FAC453 Q30438582-E31A5ACE-8EBB-4A95-A13C-C697CC720153 Q30469762-2E03BCE5-B21C-4CC1-A1D8-96EDD62ED17B Q30479606-4D8CF5BE-FA17-45ED-A813-A77991D3DEB4 Q30685445-0ECC2D87-CD29-43E3-908D-AC62915F5911 Q30778987-0184BE97-6A4A-4264-9F13-333F257A589A

P2860

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

http://www.wikidata.org/entity/Q34323096

description

2004 nî lūn-bûn

@nan

2004 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Prevalence of prostate cancer ...... l < or =4.0 ng per milliliter.

@ast

Prevalence of prostate cancer ...... l < or =4.0 ng per milliliter.

@en

Prevalence of prostate cancer ...... l < or =4.0 ng per milliliter.

@nl

type

label

Prevalence of prostate cancer ...... l < or =4.0 ng per milliliter.

@ast

Prevalence of prostate cancer ...... l < or =4.0 ng per milliliter.

@en

Prevalence of prostate cancer ...... l < or =4.0 ng per milliliter.

@nl

prefLabel

Prevalence of prostate cancer ...... l < or =4.0 ng per milliliter.

@ast

Prevalence of prostate cancer ...... l < or =4.0 ng per milliliter.

@en

Prevalence of prostate cancer ...... l < or =4.0 ng per milliliter.

@nl

P1433

Q34323096-AF94B9B9-0897-481B-8DF5-749260C6BF51

P1476

Q34323096-C6CC85F7-D7FA-4B73-B686-3876EF72744F

P2093

Q34323096-113DD934-EC85-458B-94AC-56D0CB91EE8C

Q34323096-3A994B20-2A3A-4D8F-93BB-485E43756A5A

Q34323096-3B19DE05-61FA-4D6C-BD04-96720AC7ADED

Q34323096-499424CE-3ABC-4F03-AAE2-7C69A4B19394

Q34323096-6CFA8B3F-29D3-4754-9739-4799815C3FB2

Q34323096-8BD478AB-68BA-41E3-AA1B-D9C2C13C9E35

Q34323096-C1351D84-9131-47DB-8F15-4A62120F7A77

Q34323096-C4A3430C-5A0D-4021-9A79-B9681B6BA2E8

Q34323096-CDF13565-5030-4E53-BA5B-836469C489D0

Q34323096-CE98C270-926D-4ECD-A0A6-89EC569E4A2D

P304

Q34323096-5619CC2E-3839-4A10-8284-2F0FFAE9BA77

P31

Q34323096-21F4B9AC-742F-4AAE-A183-333A94DB5F92

P356

Q34323096-13927A53-E96B-4602-9E4F-748FF8607ABC

P407

Q34323096-C2416507-C359-482A-A6D9-33F17B9CAF9B

P433

Q34323096-FF84F041-40D1-4773-9F2B-2079337B17AD

P478

Q34323096-41FFEAC4-8AD1-4553-BC7D-D6F5E888B3D4

P577

Q34323096-09F31FCB-73C9-4A5C-930F-FA2BC98CECA3

P698

Q34323096-4A83D2C9-A257-4EB0-90A9-FC8CC1B62A2B

P356

P1433

The New England Journal of Medicine

P1476

Prevalence of prostate cancer ...... l < or =4.0 ng per milliliter.

@en

P2093

Catherine M Tangen

http://www.w3.org/2001/XMLSchema#string

Charles A Coltman

http://www.w3.org/2001/XMLSchema#string

Donna K Pauler

http://www.w3.org/2001/XMLSchema#string

E David Crawford

http://www.w3.org/2001/XMLSchema#string

Howard L Parnes

http://www.w3.org/2001/XMLSchema#string

Ian M Thompson

http://www.w3.org/2001/XMLSchema#string

John J Crowley

http://www.w3.org/2001/XMLSchema#string

Leslie G Ford

http://www.w3.org/2001/XMLSchema#string

Lori M Minasian

http://www.w3.org/2001/XMLSchema#string

M Scott Lucia

http://www.w3.org/2001/XMLSchema#string

P304

2239-2246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA031918

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

350

http://www.w3.org/2001/XMLSchema#string

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15163773

http://www.w3.org/2001/XMLSchema#string